J&J’s $6.5B Momenta Buy Pays Off With Phase II Sjögren’s Disease Win | BioSpace

Published: Jun 17, 2024 By Tristan Manalac

J&J Vision/iStock, Sundry Photography

Pictured: Sign at J&J Vision offices in Silicon Valley/iStock, Sundry Photography

Johnson & Johnson on Saturday posted promising data from the Phase II DAHLIAS study of its investigational FcRn blocker nipocalimab, demonstrating significant symptomatic improvement in patients with the chronic autoimmune Sjögren’s disease.

At 24 weeks, patients treated with nipocalimab saw a “statistically significant and clinically meaningful improvement” in the ClinESSDAI score, a composite scale specific for Sjögren’s disease that measures disease activity across 11 organ systems. Data were sparse but the pharma revealed that the improvement in ClinESSDAI scores had a p-value of 0.002 versus placebo.

In addition, patients showed response to nipocalimab as early as week 4 with the treatment effects persisting through 24 weeks of treatment.

Nipocalimab also elicited “clinically meaningful” improvements in key…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks